Monoamine Reuptake Inhibitor
Monoamine reuptake inhibitors block the presynaptic transporters that clear norepinephrine (NET), dopamine (DAT), and serotonin (SERT) from the synaptic cleft, prolonging neurotransmission. The class spans selective single-transporter inhibitors and triple reuptake inhibitors. Tesofensine is a triple monoamine reuptake inhibitor originally developed for Parkinson's and Alzheimer's disease; the Phase 2 obesity signal was discovered as an off-target effect and is the basis for ongoing weight-management trials.
